Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.

Journal:

Journal of Clinical Oncology

Published:

2026-02-25

DOI:

10.1200/jco-25-01796

Affiliations:

33

Authors:

31

Go to article

Institutions	Authors	Share
Zhongda Hospital, SEU, China	3.600000	0.12
Southeast University (SEU), China	3.200000	0.10
Hengrui, China	3.000000	0.10
The Affiliated Hospital of Qingdao University, China	1.000000	0.03
Affiliated Hospital, XZMC, China	1.000000	0.03
Fujian Medical University Union Hospital, China	1.000000	0.03
Second Hospital of Shandong University, China	1.000000	0.03
The First Affiliated Hospital, USTC, China	1.000000	0.03
Yanbian University Hospital, YBU, China	1.000000	0.03
Nanfang Hospital, China	1.000000	0.03
Hunan Cancer Hospital, China	1.000000	0.03
Henan Cancer Hospital, ZZU, China	1.000000	0.03
Ganzhou City People’s Hospital, China	1.000000	0.03
Tumor Hospital of Guangxi Medical University, China	1.000000	0.03
Cancer Hospital of Yunnan Province, China	1.000000	0.03
The First Hospital of China Medical University, China	1.000000	0.03
Mengchao Hepatobiliary Hospital of Fujian Medical University, China	1.000000	0.03
Sun Yat-sen University Cancer Center (SYSUCC), SYSU, China	1.000000	0.03
Guizhou Cancer Hospital, Guizhou Medical University, China	1.000000	0.03
China Medical University (CMU), China	0.500000	0.02
Liaoning Cancer Hospital and Institute, China	0.500000	0.02
Zhuhai People's Hospital, China	0.500000	0.02
Jinan University (JNU), China	0.500000	0.02
Lishui Municipal Central Hospital, China	0.500000	0.02
Zhejiang University (ZJU), China	0.500000	0.02
Zhejiang Cancer Hospital (ZJCH), China	0.500000	0.02
Hangzhou Institute of Medicine (HIM), CAS, China	0.500000	0.02
Fujian Medical University, China	0.500000	0.02
Fujian Cancer Hospital, China	0.500000	0.02
State Key Laboratory of Digital Medical Engineering, China	0.200000	0.01

Interested in Oncology and Carcinogenesis?